Statistically significant interactions existed between COPD/asthma, female sex, ET phenotype, JAK2 positive status, hydroxyurea use, and the presence of additional cardiovascular risk factors with thrombotic risk (interaction p < 0.050 for all analyses), with a near-significant p value for high-risk disease (interaction p = 0.063). The gene discussed is JAK2; the disease is asthma.